.As part of its last consensus deliberations (IWWM-7, Newport, Rhode Island, August 2012) , the panel considered the results from phase II studies of several chemoimmunotherapy regimens, novel drugs (alone or with rituximab)and of emerging novel targeted agents (ofatumumab, everolimus, perifosine, enzastaurin, panobinostat, carfilzomib, ibrutinib) ,examined these data and updated its recommendations, which are presented herein.
The consensus panels have recommended that individual patient considerations should be weighed for the choice of therapy, including the need for rapid disease control, age, candidacy for autologous transplantation, co-morbidities, presence of cytopenias, hyperviscosity, lymphadenopathy, IgM-related end-organ damage and patients' preferences.
Based on available data, the panel provides guidance on the management of patients with WM adjusted to specific conditions and complications of the disease both for the initial therapy and for relapsed or refractory disease.
Major changes since the last published recommendations
Rituximab-based regimens remain a recommended primary therapy for most patients with WM. As per the previous recommendations of IWWM-4 6 , DRC remains a primary choice but, combinations such as R-CHOP are no longer considered a first line choice; instead bendamustine-rituximab (BR) is now a primary treatment option, especially for patients with high tumor bulk. In the current recommendations bortezomib-rituximab combinations may also be considered a primary option for patients with specific high risk features (i.e. hyperviscosity) or in younger patients for whom avoidance of alkylator therapy is sought.
Fludarabine-based combinations are not recommended for primary therapy but remain an option for patients with relapsed/refractory disease with adequate performance status. In patients who may be candidates for single agent oral therapy, oral fludarabine (if available) is recommended over chlorambucil (table 3) .
Risk stratification
The importance of a prognostic system for the risk stratification of patients with WM and as a tool for study comparisons has been emphasized 6 . In IPSSWM five covariates (age >65 7 . IPSSWM has been validated externally and its prognostic significance has been confirmed [8] [9] [10] . Results per IPSSWM risk category are increasingly reported and are used for stratification in randomized clinical trials. However, the use of IPSSWM in making treatment decisions remains to be delineated.
Justifying treatment initiation
Not all patients with a diagnosis of WM need immediate therapy. Criteria for the initiation of therapy (proposed in the IWWM-2 consensus panel and confirmed in IWWM-7) are presented in Table 1 . For patients who do not fulfill the criteria in table 1 and in whom only laboratory evidence may indicate a possible development of symptomatic disease (such as a minor decrease in hemoglobin level, but >10 gr/dl, or mild increases in IgM or mild increase of lymphadenopathy or splenomegaly without discomfort for the patient), close observation is recommended 3 .
Risk assessment for progression to symptomatic disease and follow up recommendations
IgM-MGUS or asymptomatic WM are increasingly diagnosed because more individuals undergo a serum protein electrophoresis as part of a routine laboratory assessment. The diagnosis of asymptomatic WM requires the demonstration of infiltration of the bone marrow by at least 10% clonal lymphoplasmacytic cells on trephine biopsy, or a monoclonal IgM above 3 gr/dl, and no end-organ damage or symptoms 11 .
The median time to initiation of therapy for asymptomatic patients in the SWOG-S9003 study exceeded 7 years 12 .In the series by Kyle et al, the cumulative probability of progression for patientswith asymptomatic WM was 6%, 39%, 59%& 68% at 1, 3, 5 &10 years respectively 11 and 75% required therapy during a median of 15 years of follow-up. Lower hemoglobin [11] [12] , extensive bone marrowinfiltration 11 , size of serum M-spike 11 and β -microgobulin levels 12 were significant predictors of an eventual need for therapy.
There are no data to justify early initiation of treatment and patients with asymptomatic WM should be followed without therapy, preferably every 3 months for the first year in order to evaluate the pace of disease progression and, if stable, at more extended intervals thereafter. The risk of progression remains and individuals with asymptomatic WM should be followed lifelong.
Evaluation of response to therapy
The consensus-based uniform response criteria for WM, based mainly on the degree of Mprotein reduction, were recently updated [5] [6] 13 (Table 2) .Caution is advised in the early evaluation of response during rituximab-based therapy (or other anti-CD20 monoclonal antibodies), because of the common "IgM flare" [14] [15] [16] which does not necessarily imply disease progression; in most cases will resolve but, if necessary, additional tests maybe performed to discriminate from disease progression. In patients treated with agents such as bortezomib or everolimus, tumor reduction in the bone marrow may not be proportional to the suppression of IgM levels [17] [18] [19] [20] . Thus, the variability of the IgM kinetics with various therapies should be taken into account and in discordant cases additional investigations should be considered.
New treatment options for patients with WM

Bendamustine
In .Prophylaxis against herpes zoster is strongly recommended.
Primary therapy with bortezomib is recommended for patients with high levels of IgM, with symptoms of or, at risk of developing hyperviscosity syndrome, symptomatic cryoglobulinemia or cold agglutinemia, amyloidosis and renal impairment.
Carfilzomib, a second generation proteasome inhibitor, is associated with a low risk of neurotoxicity in myeloma patients and was recently evaluated in combination with rituximab and dexamethasone(CaRD), mainly in untreatedWMpatients 32 . The schedule of carfilzomib was attenuated (days 1,2 &8,9) compared to myeloma dosing, and maintenance therapy (days 1,2 only) was given every 8 weeks for 8 cycles. Overall response rate was87%
(≥VGPR in 35%),and no grade≥3 neuropathy was observed. With a median follow-up of 15.4 months, 20/31(65%) patients remain progression-free. CaRD therefore represents a novel neuropathy-sparing option for proteasome-inhibitor based therapy for WM. Pomalidomide is under investigation.
Monoclonal antibody therapy
Rituximab
Single agent rituximab is moderately active (responses rates of~30%);more extended administration is associated with higher response rates. . Due to the lack of prospective data the use of maintenance rituximab is not routinely recommended.
Ofatumumab
Ofatumumab is a fully human monoclonal anti-CD20 antibody approved for the treatment of patients with CLL. Ofatumumab was given to37 patients (28 with relapsed/refractory and 9
with untreated WM) 43 at two dose levels (four weekly infusions of 1000 vs 2000 mg)
following a dose of 300 mg on the first week-non progressing patients received a second cycle at week 16. After the first cycle, 11(30%) achieved PR and 7(19%) a MR; twelve patients received a second cycle. The ≥ MRs after both cycles were 59%(PR in 38%), somewhat higher with higher doses(47% vs 68%), in therapy-naïve(6/9, 67%) and rituximabnaïve(9/12, 75%) than in rituximab-exposed patients(13/25, 52%). Infusion-related reactions were common especially during the first dose; mild infections were also common and "IgM flare" was observed. Ofatumumab has promising activity, may be active in patients with prior exposure to rituximab and may be considered for patients intolerant to rituximab, however, more data is needed in rituximab-refractory disease. Combinations of ofatumumab with other agents in WM are under investigation.
Alemtuzumab
CD52 is highly expressed in lymphoplasmacytic cells; however, the toxicity of the anti-CD52
antibody alemtuzumab is high, especially infectious complications, most notably CMV reactivation. Mature results (median follow-up 64 months) 44 from 28 patients(23 previously treated and 12(46%) refractory to the most recent therapy)indicated the activity of alemtuzumab (≥PR in36% and 39% MRs, median TTP14.5 months) but toxicity was significant, including deaths of patients while on therapy. CMV reactivation occurred in 18%
and new-onset autoimmune thrombocytopenia occurred in 4(14%) patients. Based on the above results, the toxicity of the drug must be weighed against available treatment options and on an individual and restrictive basis.
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Management of newly diagnosed patients who require therapy for WM
The data on therapy of WM come mainly from non-randomized studies since only few randomized studies have been conducted in the field. Based on the available data as well as the experience from the treatment of patients with low grade lymphomas, specific recommendations can be made based on individual patient needs (Table 4) .
A. Patients with WM related cytopenias or organomegaly or bulky lymphadenopathy
Most patients with WM require therapy because of cytopenias, most commonly anemia, 
B. Patients with symptomatic hyperviscosity, cryoglobulinemia or cold agglutinemia
Morbidity due to paraprotein-mediated hyperviscosity, cryoglobulinemia or cold agglutinemia is common. Rituximab-associated "IgM flare" may worsen paraprotein-related symptoms.
Plasmapheresis should be considered for patients with symptomatic hyperviscosity and/or severe cryoglobulinemia and cold agglutinemia. "Preemptive" plasmapheresis before rituximab may be considered for patients with IgM≥4 g/dLin order to avoid symptomatic "IgM flare". In patients without symptomatic hyperviscosity, bortezomib may rapidly reduce IgM levels; induction with single-agent bortezomib can be considered before institution of rituximab (as in BDR)
29
. Weekly and/or subcutaneous administration of bortezomib is preferred. In patients at high risk for neuropathy bendamustine can be considered; FCR is very effective but toxic. For patients with cold agglutinin disease requiring therapy, fludarabine/rituximab combination is superior over rituximab alone 46 ; however, toxicity should be weighed against combinations such as DRC, BDR or bendamustine/rituximab.
C. Patients with paraprotein-related neuropathy
The treatment of IgM-related neuropathy may initially involve a course of plasmapheresis, particularly in patients with an aggressive course of progressing neuropathy.
Plasmapheresis should not be used as a permanent modality. Systemic chemotherapy with rituximab resulted in improvement in sensory function in several studies, including a placebo .
D. Patients with IgM-associated amyloidosis
IgM-associated AL amyloidosis is a rare condition with distinctive clinical characteristics 52-53 .
These patients are fragile, due to systemic amyloid organ involvement and require a dedicated approach. Treatment should aim at the rapid elimination of the amyloidogenic light chains, with monitoring of the free light chains and cardiac biomarkers. There is limited evidence on the applicability and outcome of treatment with regimens designed for WM to IgM-AL amyloidosis [53] [54] [55] [56] [57] . In selected patients, ASCT may be considered. Given the activity in patients with non-IgM AL amyloidosis and in WM, bortezomib-based therapy could be used in carefully selected patients 29, 56 .
Salvage therapy
The panel encourages the participation of patients with relapsed or refractory WM in clinical trials exploring novel agents or strategies. Outside clinical trials treatment options depend on the duration and response to prior therapies, the patient's overall condition and age, and candidacy for ASCT.
Administering the same regimen used for primary treatment is reasonable in patients who achieved responses that lasted for at least 12 months; otherwise, use of an alternate single agent or combination is recommended. Updated results from the phase II DRC study indicate that this is an effective strategy for many patients 40 .
For patients with short-lasting remissions (<12 months) or with progressive disease/resistance to a first-line regimen, second-line treatment should include agents of a Bortezomib in combination with rituximab and/or dexamethasone is reasonable but neurotoxicity is of concern. Bendamustine-based therapy is effective mostly in combination with rituximab. FCR is effective but toxic. Ofatumumab for rituximab-intolerant or resistant patients maybe considered. Everolimus or alemtuzumab may be considered for selected patients with very limited treatment options, which should be followed closely for toxicity.
Stem cell transplantation (SCT) for patients with WM
High dose therapy with autologous-SCT is an option for salvage therapy in selected patients with chemosensitive disease; patients with several lines of prior therapies (≥3 lines) appear to have limited benefit from autologous-SCT 58 . As part of primary therapy autoSCT could be considered in selected young patients with high risk IPSSWM and elevated LDH. The use of myeloablative or non-myeloablative allogeneic SCT is less defined. Younger patients with slowly progressing disease may be better candidates for allo-SCT. However, in view of the increasing treatment options and the high morbidity and mortality associated with allo-SCT, the opinion of the panel is that this therapy should preferably be considered in the context of a clinical trial.
Management of Patients Intolerant to Rituximab
Rituximab is a chimeric (mouse/human) monoclonal antibody and may be intolerable in some patients, mainly due to major infusions reactions. Ofatumumab is a fully human monoclonal antibody and has been successfully administered in patients with prior rituximab-resistant disease and in patients intolerant to rituximab."IgM flare" is also observed with ofatumumab therefore similar precautions as with rituximab should be considered.
Future perspectives
The identification of the common somatic mutation in MyD88 offered the opportunity for a more targeted approach. 6 . For personal use only. on July 16, 2014. by guest bloodjournal.hematologylibrary.org From 
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